Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Advanced or Metastatic Solid Tumors
NCT05155332Phase 1Suspended
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Primary completion
- Dec 2027
- Countries
- 10
01
Overview
Phase 1, open-label trial of VSV-GP in solid tumor (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities at 21 days and Objective Response at 49 months. Started Mar 2022; status: suspended.
02
Drugs
VSV-GP
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05155332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155332.